# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### **SCHEDULE 13G**

UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )\*

## TransCode Therapeutics, Inc.

(Name of Issuer)

Common Stock, \$0.0001 par value per share (Title of Class of Securities)

89357L105 (CUSIP Number)

<u>December 31, 2021</u> (Date of Event Which Requires Filing of this Statement)

	<del></del>	
Che	eck the appropriate box to designate the rule pursuant to which this Schedu	le is filed:
	☐ Rule 13d-1(b)	
	☐ Rule 13d-1(c)	
	⊠ Rule 13d-1(d)	
* -	The remainder of this sever mass shall be filled out for a remarking negroup?	initial filing on this

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	NAMES OF REPORTING PERSONS							
	Zdravka Medarova							
2.			APPROPRIATE BOX IF A MEMBER OF A GROUP					
	(a) (b) (c)							
3.	SEC USE ONLY							
4.	CITIZENSHIP OR PLACE OF ORGANIZATION							
NII IM (D)	United States of America							
NUMBER OF		5.	SOLE VOTING POWER					
	SHARES BENEFICIALLY		1,618,497 (1)					
OWNE			1,010,477 (1)					
EAC								
REPOR								
PERS								
WIT	Ή							
		6.	SHARED VOTING POWER					
			0					
		7.	SOLE DISPOSITIVE POWER					
			1,618,497 (1)					
		8.	SHARED DISPOSITIVE POWER					
	9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON							
9.	AUUKEUATE AMUUNT BENEFICIALLY OWNED BY EACH KEPUKTING PEKSUN							
	1,618,497 (1)							
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES							
10.	CHECK BOA II THE AUGREDATE ANIOUNT IN NOW (7) EACLUDES CERTAIN SHARES							
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9							
	12.5% (2)							
12.	TYPE OF REPORTING PERSON							

**SCHEDULE 13G** 

Page 2 of 5 Pages

CUSIP No. 89357L105

ΙN

- (1) Consists of (i) 1,552,787 shares of Common Stock held directly by the Reporting Person and (ii) 65,710 shares issuable to the Reporting Person upon exercise of stock options exercisable within 60 days of December 31, 2021.
- (2) Percentage ownership is calculated based on (i) 12,904,574 shares of Common Stock outstanding, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 15, 2021, plus (ii) 65,710 shares of Common Stock underlying stock options held by the Reporting Person that are exercisable within 60 days of December 31, 2021, which are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i).

CUSIP No. 89357L105				] s	CHEDULE 13G		Page 3 of 5 Pages	
Item 1.		Issuer						
	(a)	Name of Issu	uer:					
		TransCode T	Therapeutics, Inc	c. (the " <u>Issuer</u> ")				
	(b)	Address of I	ssuer's Principa	l Executive Offices:				
		6 Liberty Sq Boston, MA						
Item 2.		Filing Perso	on					
(a) – (c) Name of Persons Filing; Address; Citizenship:								
	This statement on Schedule 13G is filed by Zdravka Medarova (the "Reporting Person"), a citizen of the United States of Americ principal business address of the Reporting Person is c/o TransCode Therapeutics, Inc., 6 Liberty Square, #2382, Boston, MA 02							
	(d)	(d) Title of Class of Securities:						
		Common Stock, par value \$0.0001 per share						
	(e)	CUSIP Number:						
89357L105								
Item 3.	Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:					on filing is a:		
	(a)	□ Broke	er or dealer regis	tered under Section 15	of the Act;			
	(b)	□ Bank	as defined in Se	ction 3(a)(6) of the Act	. ,			
	(c)	□ Insura	ince company as	s defined in Section 3(a	)(19) of the Act;			
	(d)	□ Invest	ment company	registered under Section	n 8 of the Investment Compa	any Act of 1	940;	
	(e)	☐ An inv	vestment advise	r in accordance with Ru	ale 13d-1(b)(1)(ii)(E);			
	(f)	☐ An em	nployee benefit	plan or endowment fun	d in accordance with Rule 1	3d-1(b)(1)(ii	i)(F);	
	(g)	☐ A pare	ent holding com	pany or control person	in accordance with Rule 13d	d-1(b)(1)(ii)(	(G);	
	(h)	☐ A savi	ings associations	s as defined in Section	3(b) of the Federal Deposit	Insurance Ad	et (12 U.S.C. 1813);	
	(i)		rch plan that is of 1940;	excluded from the defin	nition of an investment comp	oany under s	ection 3(c)(14) of the Investment Company	
	(j)	□ A non	-U.S. institution	in accordance with Ru	ale 240.13d-1(b)(1)(ii)(J);			
	(k)			with Rule 240.13d-1(b the type of institution:	)(1)(ii)(K). If filing as a non	-U.S. institu	tion in accordance with Rule 240.13d-1(b)(1)	
		If filing as a n	on-U.S. instituti	ion in accordance with	§240.13d-1(b)(1)(ii)(J), plea	ase specify th	ne type of institution:	

CUSIP No. 89357L105 SCHEDULE 13G Page 4 of 5 Pages

### Item 4. Ownership.

(a) and (b) Amount beneficially owned; Percent of class:

As of December 31, 2021, the Reporting Person beneficially owned an aggregate of 1,618,497 shares of Common Stock, which consisted of (i) 1,552,787 shares of Common Stock held directly by the Reporting Person and (ii) 65,710 shares of Common Stock issuable to the Reporting Person upon exercise of stock options exercisable within 60 days of December 31, 2021, representing approximately 12.5% of the outstanding shares of Common Stock. The percent of class was calculated based on (i) 12,904,574 shares of Common Stock outstanding, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 15, 2021, plus (ii) 65,710 shares of Common Stock underlying stock options held by the Reporting Person that are exercisable within 60 days of December 31, 2021, which are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i).

(c) Number of shares as to which such person has:

	Number of Shares of Common Stock			
Reporting Person	(i)	(ii)	(iii)	(iv)
Zdravka Medarova	1,618,497	0	1,618,497	0

- (i) Sole power to vote or direct the vote
- (ii) Shared power to vote or to direct the vote
- (iii) Sole power to dispose or to direct the disposition of
- (iv) Shared power to dispose or to direct the disposition of

### Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

Not applicable.

SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: December 19, 2022
/s/ Zdravka Medarova ZDRAVKA MEDAROVA

**SCHEDULE 13G** 

Page 5 of 5 Pages

CUSIP No. 89357L105